Altogether these findings suggest that the DPP-4 inhibitor linagliptin has a pleiotropic effect that is incretin- and glucose-lowering- independent, and which confers protection against kidney fibrosis in experimental DN through miRNA modulation and the inhibition of DPP-4 interaction with other proteins. Here, DPP4 is linked to liver dysplastic nodule.